Treatment Of Pediatric Osteoporosis Research Articles

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

Causes, diagnosis, and treatment of pediatric osteoporosis

Causes, diagnosis, and treatment of pediatric osteoporosis

Ibandronate in the treatment of pediatric osteoporosis

We administered oral ibandronate (once a month) to 7 children (6 boys) with low bone mineral density and prevalent low energy fractures. We observed a significant increase (17%) in bone density after one year and additional 3% increase after second year. No further fractures occurred.

Diagnosis and treatment of pediatric osteoporosis.

Progress toward identifying and treating disorders of bone fragility in pediatric patients has been considerable in recent years. This article will summarize several key advances in the management of osteoporosis in children and adolescents. Recommendations from the 2013 pediatric Position Development Conference provide expert guidance for evaluating bone health in younger patients. The diagnosis of pediatric osteoporosis can be made in a child with low-trauma vertebral fractures or a combination of low bone mass and long bone fractures. Management of bone fragility includes optimizing nutrition, activity, and treatment of the underlying disease. Pharmacologic agents can be considered if these measures fail to prevent further bone loss or fractures. Although the efficacy and safety of several intravenous and oral bisphosphonates have been examined, there is still no consensus on the optimal drug, dose, or duration of treatment. Observational studies of children with secondary osteoporosis provide insight into risk factors for fracture or the potential for recovery. Despite advances in the diagnosis and treatment of pediatric osteoporosis, more research is needed. Randomized controlled trials of pharmacologic agents should be defined to target those identified at the highest risk by observational studies. http://links.lww.com/COE/A9

Ibandronate in the treatment of pediatric osteoporosis

Searchable abstracts of presentations at key conferences on calcified tissues ISSN 2052-1219 (online)

Use of bisphosphonates in the treatment of pediatric osteoporosis

Bisphosphonates are increasingly prescribed for children with primary and secondary osteoporosis. Despite this, many questions remain as to the optimal agent, and the dose and duration of therapy, particularly considering the unique issues related to the growing skeleton. While much is now understood regarding their use in one of the most debilitating forms of childhood osteoporosis (osteogenesis imperfecta), their role in the treatment of secondary osteoporosis is less clearly defined. The purpose of this review is to highlight the impact of bisphosphonate use on the growing skeleton and to review the current evidence for bisphosphonate administration in primary and secondary childhood osteoporosis. In particular, we discuss the evidence for clinical benefit (including functional outcomes beyond bone mineral density) and review the issues related to known and theoretical side effects. Finally, we provide specific recommendations for the use of bisphosphonates in pediatric osteoporosis, including guidelin...